株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

sterna biologicals Gmbh & Co KGの製品パイプライン分析

sterna biologicals Gmbh & Co KG - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 293981
出版日 ページ情報 英文 25 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
sterna biologicals Gmbh & Co KGの製品パイプライン分析 sterna biologicals Gmbh & Co KG - Product Pipeline Review - 2015
出版日: 2015年12月16日 ページ情報: 英文 25 Pages
概要

sterna biologicals Gmbh & Co KGはドイツに本社をおくバイオ医薬品製造企業で、気管支炎、アトピー性皮膚炎、乾癬、慢性閉塞性肺疾患といった肺および皮膚の慢性炎症疾患の治療薬を開発しています。

当レポートでは、sterna biologicals Gmbh & Co KGにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

sterna biologicals Gmbh & Co KGの基本情報

  • sterna biologicals Gmbh & Co KGの概要
  • 主要情報
  • 企業情報

sterna biologicals Gmbh & Co KG:R&Dの概要

  • 主な治療範囲

sterna biologicals Gmbh & Co KG:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

sterna biologicals Gmbh & Co KG:パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

sterna biologicals Gmbh & Co KG:薬剤プロファイル

  • SB-010
  • SB-011
  • SB-012
  • SB-020
  • SB-021

sterna biologicals Gmbh & Co KG:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

sterna biologicals Gmbh & Co KG:最新のパイプライン情報

sterna biologicals Gmbh & Co KG:本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07874CDB

Summary

Global Markets Direct's, 'sterna biologicals Gmbh & Co KG - Product Pipeline Review - 2015', provides an overview of the sterna biologicals Gmbh & Co KG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of sterna biologicals Gmbh & Co KG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of sterna biologicals Gmbh & Co KG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of sterna biologicals Gmbh & Co KG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the sterna biologicals Gmbh & Co KG's pipeline products

Reasons to buy

  • Evaluate sterna biologicals Gmbh & Co KG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of sterna biologicals Gmbh & Co KG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the sterna biologicals Gmbh & Co KG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of sterna biologicals Gmbh & Co KG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of sterna biologicals Gmbh & Co KG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of sterna biologicals Gmbh & Co KG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • sterna biologicals Gmbh & Co KG Snapshot
    • sterna biologicals Gmbh & Co KG Overview
    • Key Information
    • Key Facts
  • sterna biologicals Gmbh & Co KG - Research and Development Overview
    • Key Therapeutic Areas
  • sterna biologicals Gmbh & Co KG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • sterna biologicals Gmbh & Co KG - Pipeline Products Glance
    • sterna biologicals Gmbh & Co KG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • sterna biologicals Gmbh & Co KG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • sterna biologicals Gmbh & Co KG - Drug Profiles
    • SB-010
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SB-011
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SB-012
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SB-020
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SB-021
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • sterna biologicals Gmbh & Co KG - Pipeline Analysis
    • sterna biologicals Gmbh & Co KG - Pipeline Products by Target
    • sterna biologicals Gmbh & Co KG - Pipeline Products by Route of Administration
    • sterna biologicals Gmbh & Co KG - Pipeline Products by Molecule Type
    • sterna biologicals Gmbh & Co KG - Pipeline Products by Mechanism of Action
  • sterna biologicals Gmbh & Co KG - Recent Pipeline Updates
  • sterna biologicals Gmbh & Co KG - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • sterna biologicals Gmbh & Co KG, Key Information
  • sterna biologicals Gmbh & Co KG, Key Facts
  • sterna biologicals Gmbh & Co KG - Pipeline by Indication, 2015
  • sterna biologicals Gmbh & Co KG - Pipeline by Stage of Development, 2015
  • sterna biologicals Gmbh & Co KG - Monotherapy Products in Pipeline, 2015
  • sterna biologicals Gmbh & Co KG - Phase II, 2015
  • sterna biologicals Gmbh & Co KG - Preclinical, 2015
  • sterna biologicals Gmbh & Co KG - Pipeline by Target, 2015
  • sterna biologicals Gmbh & Co KG - Pipeline by Route of Administration, 2015
  • sterna biologicals Gmbh & Co KG - Pipeline by Molecule Type, 2015
  • sterna biologicals Gmbh & Co KG - Pipeline Products by Mechanism of Action, 2015
  • sterna biologicals Gmbh & Co KG - Recent Pipeline Updates, 2015

List of Figures

  • sterna biologicals Gmbh & Co KG - Pipeline by Top 10 Indication, 2015
  • sterna biologicals Gmbh & Co KG - Pipeline by Stage of Development, 2015
  • sterna biologicals Gmbh & Co KG - Monotherapy Products in Pipeline, 2015
  • sterna biologicals Gmbh & Co KG - Pipeline by Top 10 Route of Administration, 2015
  • sterna biologicals Gmbh & Co KG - Pipeline by Top 10 Molecule Type, 2015
Back to Top